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Impact of the Metabolic Syndrome on the Clinical Outcome of 
Patients with Acute ST-Elevation Myocardial Infarction
We sought to determine the prevalence of metabolic syndrome (MS) in patients with acute 
myocardial infarction and its effect on clinical outcomes. Employing data from the Korea 
Acute Myocardial Infarction Registry, a total of 1,990 patients suffered from acute ST-
elevation myocardial infarction (STEMI) between November 2005 and December 2006 
were categorized according to the National Cholesterol Education Program-Adult 
Treatment Panel III criteria of MS. Primary study outcomes included major adverse cardiac 
events (MACE) during one-year follow-up. Patients were grouped based on existence of 
MS: group I: MS (n=1,182, 777 men, 62.8±12.3 yr); group II: Non-MS (n=808, 675 men, 
64.2±13.1 yr). Group I showed lower left ventricular ejection fraction (LVEF) (P=0.005). 
There were no differences between two groups in the coronary angiographic findings 
except for multivessel involvement (P=0.01). The incidence of in-hospital death was higher 
in group I than in group II (P=0.047), but the rates of composite MACE during one-year 
clinical follow-up showed no significant differences. Multivariate analysis showed that low 
LVEF, old age, MS, low high density lipoprotein cholesterol and multivessel involvement 
were associated with high in-hospital death rate. In conclusion, MS is an important 
predictor for in-hospital death in patients with STEMI. 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Metabolic syndrome (MS) is characterized by the clustering of 
risk factors related to insulin resistance (IR) and is associated 
with an increased risk of cardiovascular disease (1-5). In 2001, 
the National Cholesterol Education Program-Adult Treatment 
Panel (NCEP-ATP) III provided a new definition for MS, and 
this is based on simple clinical criteria and is considered as a 
prognostic indicator of vascular risk in patients with no overt 
coronary artery disease (1-4). Most recently, in 2005, American 
Heart Association/National Heart Lung and Blood Institute 
(AHA/NHLBI) presented new criteria modified from NCEP-
ATP III criteria (6). Several studies based on populations at high 
risk for cardiovascular disease such as patients with hyperten-
sion or type 2 diabetes mellitus (DM) have shown a very high 
prevalence of MS from 35% to 80% (7, 8). In one cohort study, 
more than half of symptomatic patients who underwent elec-
tive coronary angiography and showed angiographic criteria 
for coronary artery disease, fulfilled the criteria for MS (9). Fur-
thermore, a recent study in patients with established symptom-
atic vascular disease (e.g. coronary artery disease, stroke, or pe-
ripheral arterial disease) showed that the prevalence of MS cor-
related with the extent of vascular damage (10). Because scanty 
data are available on the prognostic role of MS in patients with Lee MG, et al.  •  Metabolic Syndrome in Acute Myocardial Infarction
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acute myocardial infarction (MI) (11), authors attempted to as-
sess the prevalence and clinical characteristics of MS, and to 
validate its association with cardiovascular events in acute ST-
elevation MI (STEMI) patients.
MATERIALS AND METHODS
Study subjects
The Korea Acute Myocardial Infarction Registry (KAMIR) is a 
prospective, multi-center, observational registry (CNUH IRB 
No. 05-0049) designed to examine current epidemiology, in-
hospital management, and outcome of patients with acute MI 
in Korea established for the commemoration of the 50th anni-
versary of the Korean Circulation Society (12, 13). Among the 
7,780 patients with acute MI between November 2005 and Oc-
tober 2006, eligible 1,990 patients with acute STEMI were sort-
ed by the diagnostic criteria of MS and followed up during 1 yr. 
Exclusion criteria were STEMI who could not be sorted by the 
diagnostic criteria of MS due to lack of data and non-STEMI. 
Total number of STEMI patients were 4,625 and the number of 
patients excluded were 2,635. These included patients were 
grouped based on existence of MS: Group I: The patients who 
were assigned to MS group, Group II: The patients who were as-
signed to non-MS group.
Study design
Patients were enrolled in the registry if they were admitted to 
participating hospitals with a suspected diagnosis of MI. A final 
diagnosis of MI was made in the presence of serial increases in 
serum biochemical markers of cardiac necrosis, associated with 
typical electrocardiographic changes and/or typical symptoms 
(14). Patients with ST-segment elevation ≥1 mm in ≥2 extremity 
electrocardiographic leads or ≥2 mm in ≥2 contiguous precor-
dial leads or new left bundle branch block on the admission elec-
trocardiogram were defined as having STEMI.
  We analyzed baseline demographic and clinical characteris-
tics, and relevant laboratory results. Creatinine clearance (CCr) 
was calculated using Cockroft and Gaut formula: CCr (mL/min)= 
{[140–age (yr)]*weight (kg)}/[72*serum creatinine (mg/dL)] 
(multiply by 0.85 for women). Echocardiography was performed 
in all patients before discharge. The morphology of lesion in cor-
onary angiography was classified by criteria of American Col-
lege of Cardiology/American Heart Association (ACC/AHA) (15). 
The degree of coronary flow was classified by Thrombolysis In 
Myocardial Infarction (TIMI) score (16). Major adverse cardiac 
events (MACE) were evaluated at the 1 month, 6 months, and   
1 yr clinical follow-up and were defined as the composite of 1) 
cardiac death, 2) non-cardiac death, 3) re-infarction, and 4) re-
percutaneous coronary intervention (PCI) or coronary artery 
bypass graft (CABG). Re-infarction was defined as the recurrence 
of symptoms or electrocardiographic changes in association with 
a rise in cardiac enzymes above the upper limit of normal. All 
data were recorded on a standardized, electronic, web-based 
registry at http://www.kamir.or.kr.
Definition of the MS
For the diagnosis of MS at baseline, we used the NCEP-ATP III 
criteria. Merely, central obesity was defined as waist circumfer-
ence >90 cm in men or >80 cm in women by modified ATP III 
guideline that WHO-Western Pacific Region (WPR) and Inter-
national Association for the Study of Obesity (IASO) presented 
for Asian populations in 2000. The presence of MS was analyzed 
considering the presence of the following criteria: 1) Central obe-
sity: waist circumference >90 cm (men), >80 cm (women) or 
body mass index (BMI) ≥25 kg/m
2, 2) A fasting triglyceride level 
≥150 mg/dL, 3) Reduced high density lipoprotein (HDL) cho-
lesterol: <40 mg/dL (men), <50 mg/dL (women), 4) Hyperten-
sion: blood pressure ≥130/85 mmHg or taking antihypertensive 
medication, 5) Impaired fasting glucose (IFG): fasting glucose 
≥110 mg/dL or taking medication or past history of type 2 DM. 
Patients were considered to have MS in the presence of ≥3 of 
criteria, according to the definition proposed by the AHA/NHLBI. 
Although AHA/NHLBI guideline recommended the definition 
of IFG is at or above 100 mg/dL, our study adopted NCEP-ATP 
III guideline (6).
Statistical analysis
We compared the in-hospital mortality, the admission duration 
of coronary care unit and the incidence of MACE during 1 month, 
6 months, and 1 yr clinical follow-up between two groups.
  The Statistical Package for Social Science (SPSS) for Windows, 
version 15.0 (Chicago, IL, USA) was used for all analysis. Con-
tinuous variables were expressed as mean±standard deviation 
(SD) and they were compared with the use of an unpaired Stu-
dent’s t-test. Categorial variables were compared with the use 
of the chi-square test, where appropriate. A P value less than 
0.05 was deemed as significant. Adjusted odds ratios (OR) with 
accompanying 95% confidence intervals (CI) were reported. 
We used the risk ratio with 95% CI to evaluate the association 
between significant variables and adverse outcomes. A multi-
ple logistic regression model was performed to examine the as-
sociation between the MS and adverse clinical events.
RESULTS
Baseline clinical characteristics of the study population
Among the 1,990 patients with acute STEMI who were followed 
up during one year, there were 1,182 patients with MS and 808 
patients without MS. The baseline clinical characteristics and 
laboratory findings of the study population were described in 
Tables 1, 2. Patients of group I were younger (P=0.01) and more 
likely to be women (P<0.001) than those of group II. Also, they Lee MG, et al.  •  Metabolic Syndrome in Acute Myocardial Infarction
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showed higher proportion of smoker (P<0.001), central obesity 
(P<0.001), hypertension (P<0.001) and DM (P<0.001). Group I 
showed lower left ventricular ejection fraction (LVEF) (P<0.001), 
but no significant difference in Killip class relative to group II 
(P=0.78). The levels of N-terminal pro-brain natriuretic peptide 
and CCr were higher in the group I than in the group II (P<0.001, 
P=0.002, respectively).
Coronary angiographic findings
In the group I, coronary angiography was done in 94.1% of pa-
tients during hospitalization, and 92.2% in the group II. Also, 
PCI was done in 95.6% of patients in the group I relative to 95.3% 
in the group II; and success rate of PCI showed no significant 
difference between two groups. The baseline coronary angio-
graphic characteristics are shown in Table 3. The most common 
infarct-related artery was the left anterior descending artery in 
both groups. A kind of infarct-related artery, lesion type accord-
ing to ACC/AHA classification, and TIMI flow grade before and 
after PCI showed no significant differences between two groups. 
Multivessel involvement was more prevalent in the group I than 
in the group II (P=0.01).
In-hospital outcomes and MACE
The clinical outcomes during one year follow-up are shown in 
Table 4. In-hospital mortality of total STEMI patients from KA-
MIR was 6.4% (n=296), and the estimated in-hospital mortality 
from present study was 7.5% in the group I and 5.2% in the group 
II (P=0.047). The duration of admission at the coronary care unit 
showed no significant difference between two groups. The inci-
dence of composite MACE was not significantly different be-
tween two groups in 1 month, 6 months, and 12 months clinical 
follow-up.
Multi-variate analysis of predictors of in-hospital mortality
Multivariate analysis was conducted to identify the independent 
Table 1. Baseline characteristics according to the presence of metabolic syndrome
Variables
Group I 
(n=1,182)
Group II 
(n=808)
 P
Age (yr)   62.8±12.3 64.2±13.1 0.01
Male (%)    777 (65.7) 675 (83.5) <0.001
Central obesity (%)    877 (74.2) 149 (18.4) <0.001
Past history (%)
   Smoking
   Hypertension
   Diabetes Mellitus
   Hyperlipidemia
   Familial history of coronary artery disesse
   Prior angina
   Prior myocardial infarction
   Prior percutaneous coronary intervention
   Prior coronary artery bypass graft
   675 (57.1)
   700 (59.2)
   358 (30.3)
 108 (9.1)
   93 (7.9)
   55 (4.7)
   39 (3.3)
   43 (3.6)
     4 (0.3)
558 (69.1)
207 (25.6)
148 (18.3)
47 (5.8)
61 (7.5)
42 (5.2)
18 (2.2)
35 (4.3)
  3 (0.4)
<0.001
<0.001
<0.001
0.09
0.47
0.64
0.13
0.48
0.92
Symptoms and hemodynamics on admission
Chest pain (%) 1,018 (86.1) 685 (84.7) 0.04
Dyspnea (%)   301 (25.5) 153 (18.9) <0.001
Systolic blood pressure (mmHg) 130.0±30.3 120.7±27.3 <0.001
Heart rate (beats/min)   77.5±28.0 76.0±19.7 0.21
Killip class (%)
   I
   II
   III
   IV
   875 (74.0)
   163 (13.8)
   74 (6.3)
   70 (5.9)
603 (74.6)
106 (13.2)
55 (6.8)
44 (5.4)
0.78
Echocardiogram findings
   Left ventricular ejection fraction (%)
   Total wall motion score
  49.3±12.5
  18.1±10.8
50.9±12.0
18.7±11.1
0.005
0.28
Table 2. Laboratory findings according to the presence of metabolic syndrome
Variables Group I (n=1,182) Group II (n=808)  P
Creatinine clearance (mL/min) 74.3±47.2 68.3±37.4 0.002
Fasting glucose (mg/dL) 184.3±82.0 156.7±72.5 <0.001
Creatine kinase-MB (U/L) 187.2±251.6 190.2±229.6 0.78
Troponin-I (ng/mL) 68.4±101.8 64.4±96.8 0.43
Total cholesterol (mg/dL) 187.4±46.5 177.4±39.7 <0.001
Triglyceride (mg/dL) 150.1±108.7 86.9±45.2 <0.001
Low density lipoprotein-cholesterol  
   (mg/dL)
120.8±41.1 114.0±39.0 <0.001
High density lipoprotein-cholesterol  
   (mg/dL)
42.0±11.9 49.5±11.1 <0.001
High sensitivity C-reactive protein  
   (mg/dL)
24.3±116.9 28.0±129.9 0.54
N-terminal pro-brain natriuretic  
   peptide (pg/dL)
2887.4±6938.7 1843.9±3859.7 <0.001
Table 3. Coronary angiographic findings according to the presence of metabolic syn-
drome
Variables
  Group I 
  (n=1,182)
  Group II  
  (n=808)
P
Coronary angiogram, No. (%) 1,112 (94.1) 745 (92.2) 0.18
Infarct-related artery, No. (%)
   Left main stem
   Left anterior descending artery
   Left circumflex artery
   Right coronary artery
14 (1.0)
567 (50.9)
114 (10.5)
417 (37.5)
14 (1.9)
407 (54.6)
66 (8.9)
258 (34.6)
0.28
0.12
0.32
0.21
ACC/AHA lesion type, No. (%)
   A
   B1
   B2
   C
84 (7.6)
221 (19.9)
270 (24.3)
537 (48.3)
53 (7.1)
130 (17.5)
188 (25.2)
374 (50.2)
0.38
Diseased vessel number, No. (%)
   Single vessel
   Two vessels
   Three vessels
477 (42.9)
357 (32.1)
245 (22.0)
390 (52.3)
199 (26.7)
127 (17.1)
0.01
Percutaneous coronary intervention (PCI), 
   No. (%)
1,130 (95.6) 770 (95.3) 0.77
Successful result of PCI, No. (%) 1,034 (91.5) 705 (91.6) 0.93
Pre-PCI TIMI flow grade, No. (%)
   0
   I
   II
   III
569 (50.4)
110 (9.7)
177 (15.7)
274 (24.2)
389 (52.2)
80 (10.7)
97 (13.0)
180 (24.2)
0.45
Post-PCI TIMI flow grade, No. (%)
   0
   I
   II
   III
25 (2.2)
14 (1.2)
58 (5.1)
1,034 (91.5)
12 (1.5)
11 (1.4)
36 (4.7)
711 (92.4)
0.39
ACC/AHA, American College of Cardiology/American Heart Association; TIMI, Throm-
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predictors of in-hospital mortality with using the meaningful 
factors in univariate analysis (Table 5). The independent predic-
tors of in-hospital mortality were found to be a low LVEF (P< 
0.001), old age (P<0.001), MS (P=0.002), low HDL-cholesterol 
level (P=0.003), and multivessel involvement (P=0.016) (Table 6).
DISCUSSION
Only a few studies have evaluated the prevalence of MS, as de-
fined by the NCEP-ATP III criteria, in patients with symptomat-
ic arterial disease. The results of previous studies suggested that 
MS was very common among patients with coronary artery dis-
ease, because almost a half of patients had MS and that it was 
associated with advanced vascular damage (9, 10). In contrast, 
recently, some experts have raised concerns about the clinical 
validity of MS (17, 18), and its clinical significance remained con-
troversial. Our study, based on an unselected population of pa-
tients hospitalized with MI, confirmed the high prevalence of 
MS in patients with acute STEMI. More advanced vascular dam-
age has been associated with the presence of MS in patients with 
manifest vascular disease, which may worsen the prognosis (10). 
MS represents a cluster of several risk factors, each of which may 
be involved in this poor outcome.
  The main finding of present study was that the MS was mean-
ingful predictor of in-hospital death in patients with STEMI. This 
result suggested that MS can be used for risk stratification in pa-
tients with STEMI. Among patients who have a history of acute 
MI, MS was recently shown to be associated with a higher rate 
of all-cause death and the composite of cardiovascular death, 
non-fatal stroke, and non-fatal MI (19). MS has also been shown 
to be associated with a higher incidence of severe heart failure 
following acute MI (20). In our study, MS was associated with 
increased risk of in-hospital mortality, but did not show the mean-
ingful increment of poor long term clinical outcomes. Previous 
study showed that MS was a strong predictor of late-onset DM 
in post-MI and the risk of death among patients with MS was 
mainly associated with the transformation in DM (19). If more 
prolonged follow-up period is fulfilled, it would be possible that 
long-term outcome would be meaningfully increased in patient 
with MS relative to patient without MS. There are a number of 
reasons why MS could predispose to short-term mortality. Its 
components, such as central obesity, IR, dyslipidemia, hyper-
tension, are all risk factors for endothelial dysfunction, which is 
an important factor in the pathophysiology of atherosclerosis 
and acute coronary syndromes. Hallmarks of the MS include a 
prothrombotic proinflammatory state and markers of inflam-
mation have been found to correlate with the presence of MS in 
Table 4. Clinical outcomes and major adverse cardiac events during follow-up and at 
12 months (after discharge)
Variables
  Group I 
  (n=1,182)
  Group II 
  (n=808)
P
Outcomes in-hospital period
   In-hospital death, No. (%)
   Coronary care unit admission duration (days)
   89 (7.5)
3.6±3.9
42 (5.2)
3.5±3.0
0.047
0.3
The composite of MACE at 1 month, No. (%)
   Cardiac death
   Non-cardiac death
   Myocardial infarction
   Re-percutaneous coronary intervention
   Coronary artery bypass graft
   135 (11.4)
   99 (8.4)
     4 (0.3)
   10 (0.9)
   20 (1.7)
     1 (0.1)
76 (9.4)
57 (7.1)
  2 (0.3)
  5 (0.6)
  8 (1.0)
  3 (0.4)
0.14
0.30
1.00
0.60
0.25
0.16
The composite of MACE at 6 months, No. (%)
   Cardiac death
   Non-cardiac death
   Myocardial infarction
   Re-percutaneous coronary intervention
   Coronary artery bypass graft
   232 (19.6)
 110 (9.3)
     6 (0.5)
   15 (1.3)
95 (8)
     6 (0.5)
132 (16.4)
66 (8.2)
  5 (0.6)
  7 (0.9)
51 (6.3)
  3 (0.4)
0.09
0.41
0.74
0.40
0.18
0.65
The composite of MACE at 12 months, No. (%)
   Cardiac death
   Non-cardiac death
   Myocardial infarction
   Re-percutaneous coronary intervention
   Coronary artery bypass graft
   246 (21.0)
 113 (9.6)
     8 (0.7)
   16 (1.4)
 104 (8.8)
     7 (0.6)
154 (19.1)
67 (8.3)
 11(1.4)
10 (1.2)
62 (7.7)
  4 (0.5)
0.33
0.34
0.16
0.78
0.41
0.77
Table 5. Univariate analysis for the predictors of in-hospital death
Variables Odds ratio
95% confidence 
interval
P
Low ejection fraction (≤40%) 3.873 2.454-6.111 <0.001
Old age (≥65 yr) 3.267 2.170-4.919 <0.001
Low HDL-cholesterol 2.546 1.759-3.684 <0.001
Female gender 2.179 1.516-3.130 <0.001
Hypertension 2.023 1.396-2.933 <0.001
Impaired fasting glucose or  
   type 2 diabetes mellitus
1.698 1.166-2.472 0.005
Multivessel involvement 1.738 1.116-2.707 0.013
Reperfusion time (<6 hr) 0.702 0.477-1.033 0.051
High triglyceride 0.338 0.106-1.082 0.055
Central obesity 0.648 0.452-1.108 0.069
Smoking 0.855 0.682-1.121 0.308
In-hospital death 
group
Control group P
N-terminal pro-brain  
   natriuretic peptide (pg/mL)
12,013.0±14,310.4 1,961.2±4,589.0 <0.001
Creatinine clearance (mL/min) 43.7±22.9 73.8±44.0 <0.001
HDL-cholesterol, High density lipoprotein-cholesterol.
Table 6. Multivariate analysis for the predictors of in-hospital death
Variables Odds ratio
95% confidence 
interval
 P
Low ejection fraction (≤40%) 3.98 2.338-6.776 <0.001
Old age (≥65 yr) 3.69 1.856-7.345 <0.001
Metabolic syndrome 2.65 1.673-5.348 0.002
Low HDL-cholesterol 2.38 1.340-4.223 0.003
Multivessel involvement 1.48 1.080-2.030 0.016
N-terminal pro-brain natriuretic peptide  
   (pg/mL)
1.46 0.823-1.578 0.113
Impaired fasting glucose or type 2  
   diabetes mellitus
1.51 0.857-2.650 0.154
Female gender 1.27 0.723-2.246 0.403
Hypertension 1.23 0.566-2.691 0.597
Creatinine clearance (mL/min) 1.09 0.974-1.103 0.687
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survivors of acute MI (2, 6, 21). Patients with impaired glucose 
tolerance found during admission for acute MI have an increas-
ed rate of non-fatal stroke, non-fatal MI, severe heart failure, and 
cardiovascular death (22).
  The association between MS and poor prognosis highlights 
the clinical relevance of this syndrome, especially given the high 
prevalence among patients presenting with acute MI. Patients 
with MS should be identified and cared for appropriately, given 
the increased mortality noted in this study. Although there are 
currently no specific treatments directed at the MS as a whole, 
treating the individual components via lifestyle modification 
and lipid correcting agents have shown to slow the progression 
of MS and reduce the risk of cardiovascular disease (19, 23, 24).
  This study has several limitations. First, our study is multi-cen-
ter prospective registry, and it was not a randomized, controlled 
study. Thus there was probably a selection bias when enrolling 
patients into both study groups. Second, although we assessed 
risk factors at the time of the index event, we could not reliably 
measure how long the risk factors had been present before the 
MI. Third, using high BMI as a marker for truncal adiposity may 
not have accurately classified patients as having MS. However, 
BMI and waist circumference are strongly correlated, and high 
BMI has been shown to be strongly associated with MS (25-28). 
BMI has also been used as surrogate for waist circumference in 
other analysis, making it a reasonable choice to use in defining 
the MS group (19, 26). Finally, the period of our study is relative-
ly short, because our study is a comparison of the MACE at one 
year clinical follow-up. Although there were such limitations in 
the present study, it should be emphasized that the presence of 
MS at the presentation of acue STEMI was associated with an 
increased short-term incidence of fatal events.
  Conclusively, MS is highly prevalent in the patients with acute 
STEMI and have the detrimental impact on short term outcomes, 
so awareness and preventative measures are important in hopes 
of improving outcomes in these patients.
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